(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/crwe_tech.jpg

Your Technology Source, Your Technology Team

Server Maintenance, Web Development, Mobile Application Solutions, SEO Services and more

Contact Us: contact@crwetech.com

www.CRWETech.com

ad2

http://crweworld.com/assets/images/ad/ad4.png

Place Your Ad Here! Advertise your business online on CRWE WORLD. Your Company, product, or service in front of the world!

Contact Us: contact@crweworld.com

www.CRWEWorld.com

ad3

http://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

http://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com

ad5

http://crweworld.com/assets/images/ad/Pathology_Laboratories.png

Quest Diagnostics Inc. (NYSE:DGX) offers the most extensive clinical testing network in the U.S. The Company's extensive test menu includes routine biological testing; complex and specialized molecular and gene-based testing, and anatomic pathology testing. These services primarily help identify disease or risk factors for disease and predict and monitor response to treatment.

www.QuestDiagnostics.com






661 Result: Form 10-K

Versar, Inc. Announced New Multi-Year Operations and Maintenance Contract Award by the U.S. Army Corps of Engineers for Work in Afghanistan

March 23rd, 2017

Springfield, VA / CRWE PRESS RELEASE / March 23, 2017 - Versar, Inc. (NYSE MKT: VSR) today announced that the United States Army Corps of Engineers, Transatlantic Afghanistan District (USACE-TAA), has awarded a new contract to Versar f. Read more

Bristol-Myers Squibb and CytomX Therapeutics Extend Worldwide Collaboration to Discover Probody(TM) Therapeutics for the Treatment of Cancer and Other Diseases

March 20th, 2017

* Builds upon initial 2014 alliance in oncology * Includes up to eight additional targets in oncology and other therapeutic areas * CytomX to receive $200 million upfront payment NEW YORK and SOUTH SAN FRANCISCO / CRWE PRESS RELEASE / March 20, . Read more

Hitachi Chemical Signs Agreement to Purchase from Caladrius Biosciences the Remaining 80.1% Interest in PCT for $75 Million

March 16th, 2017

Caladrius expected to emerge as a well-capitalized cell therapeutics-only development company with multiple proprietary technology platforms Conference call begins tomorrow, March 17, 2017 at 8:30 am Eastern time BASKING RIDGE, N.J. / CRWE PRES. Read more

Intel to Acquire Mobileye

March 13th, 2017

Combining Technology and Talent to Accelerate the Future of Autonomous Driving NEWS HIGHLIGHTS * Brings together Mobileye’s leading computer vision expertise with Intel’s high-performance computing and connectivity expertise to crea. Read more

ASPiRA LABs Announces Provider Status with Medi-Cal Expanding OVA1(R) Access to Over 12 Million Beneficiaries

March 06th, 2017

AUSTIN, Texas / CRWE PRESS RELEASE / March 6, 2017 — ASPiRA LABs, a Vermillion company (NASDAQ: VRML), today announced it has attained out-of-state provider status with Medi-Cal, California’s Medicaid program, for OVA1®/Multivari. Read more

Diplomat to Dispense XERMELO(TM) for Patients With Carcinoid Syndrome Diarrhea

March 06th, 2017

FLINT, Mich. / CRWE PRESS RELEASE / March 6, 2017 – The nation’s largest independent specialty pharmacy has been selected to the limited-distribution panel of XERMELO™ (telotristat ethyl). Diplomat Pharmacy, Inc. (NYSE: DPLO), wi. Read more

ASPiRA LABs Announces Contracted In-Network Agreement with Blue Cross Blue Shield of Michigan for OVA1(R)

March 01st, 2017

AUSTIN, Texas / CRWE PRESS RELEASE / March 1, 2017 — ASPiRA LABs, a Vermillion company (NASDAQ: VRML), today announced a major contracted agreement with Blue Cross Blue Shield of Michigan for ASPiRA’s U.S. FDA cleared, American Colle. Read more

Qualcomm Extends Cash Tender Offer for All Outstanding Shares of NXP

February 06th, 2017

- NXP Shareholders Approve All Items Proposed Relating To Qualcomm’s Tender Offer - SAN DIEGO / CRWE PRESS RELEASE / Feb. 6, 2017 - Qualcomm Incorporated (NASDAQ: QCOM) today announced that Qualcomm River Holdings B.V. , an indirect wholly o. Read more

EyeGate Pharma Announces Positive Top-line Data from First-in-Human Pilot Trial of Ocular Bandage Gel in Corneal Epithelial Defects

January 30th, 2017

Company Plans to Continue Development with Next Controlled Trial Q2 2017 WALTHAM, Mass. / CRWE PRESS RELEASE / January 30, 2017 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a specialty pharma. Read more

Walgreens Boots Alliance and Rite Aid Enter into Amendment and Extension to Merger Agreement

January 30th, 2017

Deerfield, Ill. and Camp Hill, Pa. / CRWE PRESS RELEASE / January 30, 2017 - Walgreens Boots Alliance, Inc. (Nasdaq: WBA) and Rite Aid Corporation (NYSE: RAD) today announced that they have entered into an amendment and extension of their previously . Read more

EyeGate Receives Additional Milestone Payment from Valeant Pharmaceuticals for EGP-437

January 09th, 2017

WALTHAM, Mass. / CRWE PRESS RELEASE / January 9, 2017 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing pro. Read more

Puma Biotechnology Expands Cohort in Phase II SUMMIT Trial of PB272 in HER2 Mutation-Positive Cancer Patients

January 06th, 2017

LOS ANGELES, Calif. / CRWE PRESS RELEASE / Jan. 6, 2017 - Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, has expanded the fourth cohort from its Phase II SUMMIT clinical trial of its lead drug candidate PB272 (neratinib) as a s. Read more

Ritter Pharmaceuticals Phase 2a Lactose Intolerance Clinical Trial Microbiome Data, Published in Proceedings of the National Academy of Science

January 03rd, 2017

LOS ANGELES, CA / CRWE PRESS RELEASE / January 3, 2017 - Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the human gut micro. Read more

Fred's Pharmacy Agrees to Acquire 865 Rite Aid Stores

December 20th, 2016

Purchase Would Create Third-Largest U.S. Drug Store Chain and Support Healthcare Growth Strategy MEMPHIS, Tenn. / CRWE PRESS RELEASE / December 20, 2016 – Fred’s Inc. (“Fred’s Pharmacy” or “the Company”) (. Read more

Uranium Resources Signs Binding Amendment for Sale of Assets

December 14th, 2016

CENTENNIAL, Colo. / CRWE PRESS RELEASE / December 14, 2016 - Uranium Resources, Inc. (Nasdaq: URRE; ASX: URI), an energy metals exploration and development company, has entered into a binding amendment to the Share Purchase Agreement (“Agreemen. Read more

Load More Content